SVB Leerink analyst Andrew Berens maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and raises the price target from $54 to $56.SVB Leerink analyst Andrew Berens maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and raises the price target from $54 to $56.